Role of O-linked N-acetylglucosamine glycosylation in neurodegenerative diseases and its clinical application prospects
- VernacularTitle:O连接N-乙酰葡萄糖胺糖基化在神经退行性疾病中的作用及临床应用前景
- Author:
Qianping JIANG
1
;
Dan YANG
;
Shilei WAN
;
Dandan XU
;
Lu CAO
;
Jing ZHOU
Author Information
- Publication Type:Journal Article
- Keywords: O-linked N-acetylglucosamine glycosylation; neurodegenerative diseases; Alzheimer's disease; Parkinson's disease; amyotrophic lateral sclerosis; Huntington's disease; review
- From: Chinese Journal of Tissue Engineering Research 2025;29(26):5704-5712
- CountryChina
- Language:Chinese
- Abstract: BACKGROUND:The abnormal aggregation of proteins and the loss of neurons are typical pathological changes observed in neurodegenerative diseases.Changes in the levels of O-linked N-acetylglucosamine glycosylation are closely related to relevant pathological changes and are promising potential therapeutic targets.OBJECTIVE:To review the role of O-linked N-acetylglucosamine glycosylation in neurodegenerative diseases and the current advancements in its clinical applications,aiming to provide new insights for the treatment of neurodegenerative disorders.METHODS:The first author conducted a literature search in the CNKI,VIP,WanFang Database,ChiCTR,Web of Science,PubMed,Cochrane Library,Clinical Trials and Alzforum,using the search terms"O-GIcNAcylation,Neurodegenerative diseases,Alzheimer's disease,Parkinson's disease,Amyotrophic lateral sclerosis,Huntington's disease,OGA inhibitors,Clinical trial"in Chinese and English.A total of 66 relevant articles were included for review.RESULTS AND CONCLUSION:O-linked N-acetylglucosamine glycosylation is involved in the development and functional regulation of neurons,and its levels gradually decrease as neuronal development matures.In neurodegenerative diseases,the pathological proteins involved are regulated by O-linked N-acetylglucosamine glycosylation.Most evidence suggests that using O-GIcNAcase inhibitors to enhance O-linked N-acetylglucosamine glycosylation levels can significantly alleviate related pathological changes,making it a potential therapeutic strategy for neurodegenerative diseases.Some O-GIcNAcase inhibitors have completed Phase I clinical trials,demonstrating good safety and tolerability.
